Keyword: Genentech

News

Biotech M&A at 4-Year High as Pharma Faces Expiring Patents

03.08.2012 - Global biotech merger volume has reached levels not seen in four years as big pharmaceutical companies pursue deals to get access to new drugs, with bankers saying therapeutic...

News

U.S. Health Advisers Back Two New Eye Treatments

27.07.2012 - A U.S. Food and Drug Administration panel on Thursday recommended two drugs for combating different forms of vision loss that can lead to blindness among a range of adults...

News

After Roche Merger, Biotech Tail Wags Big Pharma Dog

03.07.2012 - When Roche paid $46.8 billion in 2009 to gain full ownership of Genentech, fears were rife that the arrival of the Swiss men in suits would stifle the free-wheeling innovative...

News

Roche Revamps Research Ops, Cuts 1,000 U.S. Jobs

27.06.2012 - Swiss drugmaker Roche said on Tuesday it was overhauling its research operations by closing the 80-year-old New Jersey facility where Valium was discovered, cutting 1,000 jobs and...

Chemistry & Life Sciences

Fine Chemicals: The Top 10

30.05.2011 - Analysis - When comparing the fine chemicals market of today to that of 2001, a few clear differences can be seen. Fine chemicals expert Jan ­Ramakers takes an in-depth look at the...

News

Severin Schwan of Roche Sees Generic Companies and Innovators As Winners

06.12.2010 - Roche Holding Chief Executive Severin Schwan believes the survivors in the pharmaceuticals sector will be large generic drugmakers, and companies who make innovative new products...

News

Glaxosmithkline Says Roche's Herceptin Infringes Patents

22.09.2010 - Drugmaker Glaxosmithkline sued Swiss rival Roche on Tuesday for infringing a patent when it produces its cancer drug Herceptin, according to court documents filed on Monday. Glaxo...

News

Sanofi's Best Bet Still May Be Smaller Deals

04.08.2010 - Sanofi-Aventis has grabbed the headlines with its $18.4 billion bid for Genzyme, but the French drugmaker may be wiser to stick with smaller, bolt-on acquisitions. Sanofi is trying...